Abstract Over the last decade, the study of genomes has rapidly advanced to the point that genomic research now serves as the basis for many medical decisions and public health initiatives. Genetic variation is likely to contribute substantially to the variation in drug response observed across human populations. Genomic tools such as sequence variation and, more specifically, personal genome sequencing incorporating genome-wide association studies and nextgeneration sequences enable the precise prediction and treatment of disease. At present, DNA-based risk assessment for common complex diseases, application of molecular signatures and dose selection of therapeutic drugs are the important issues in personalized medicine. In order to make personalized medicine effective, these genomic techniques must be standardized and integrated into health systems and clinical workflow for prediction of disease incidence, genetic and environmental information to optimize the medical care and outcomes for each patient. Technology continues to lead the field of personalized medicine since the interpretation of the human genome is progressing as the cost and duration of genomic sequencing continue to decrease sharply. This review aimed at understanding the technologies that reveal how the changes that occur within the genome can alter their functions and the genomic variations that constitute individual susceptibility to diseases and responses to therapy.
Introduction
''Variability is the law of life, and as no two faces are the same, so no two bodies are alike and no two individuals react alike and behave alike under the abnormal conditions we know as disease'' [1] . Pharmacogenomics addresses this issue by seeking to identify genetic contributors to human variation in drug efficacy and toxicity [2] . Additionally, next-generation sequencing (NGS) technologies and genome-wide association studies represent a significant tool in translating this knowledge into a systems-level understanding of drug physiology, with the ultimate goal of developing more effective personalized clinical treatment strategies. NGS technologies represent a paradigm shift in sequencing capability [3] . NGS technologies have demonstrated the capacity to sequence DNA at unprecedented speed, thereby enabling previously unimaginable scientific achievements and novel biological applications [4] . With the completion of the Human Genome Project and rapid advances in sequencing, including NGS techniques, it is undeniable that the era of genomic medicine is upon us [5] . The generation of genome-wide sequencing data cost effectively with deep coverage in a short time frame is replacing approaches that focus on specific regions for gene discovery and clinical testing [6] . The exponential decline in sequencing costs and the constant improvement in these technologies promise to further advance the use of a patient's full genetic profile in the clinic [7] . High-throughput genomic measurements initially emerged for research purposes but are now entering the clinic [8] . With fast development and wide applications of NGS technologies, genomic sequence information is within reach of decoding life's mysteries and improving its quality. The most spectacular results of the human genome study have been provided by genome-wide association studies (GWASs). GWASs are becoming an increasingly effective tool for identifying genetic factors contributing to complex diseases [9] . GWASs for pharmacogenomic-related traits are increasingly being performed to identify loci that affect either drug response or susceptibility to adverse drug reactions. This article reviews basic concepts, general applications, and the potential impact of GWAS and NGS technologies on genomics, with particular reference to currently available and possible future platforms and bioinformatics.
Genetic Variation in Drug Response
The field of pharmacogenomics, which seeks to relate genetic variability to variability in human drug response, has evolved considerably from candidate gene studies to studies of variation across whole genomes of human populations containing individuals who exhibit a range of responses to different drugs. The initial successes in the field were often the identification of genetic variants within drug-metabolizing genes that had large effects on sensitivity to a given drug. Early pharmacogenomic studies sought primarily to identify associations between common genetic variations and drug response. More recent approaches have begun to identify mRNAs, miRNAs and other downstream events that are influenced by genetic variation and may underlie variation in pharmacologic responses. A primary aim is to uncover novel human genetic variants that affect therapeutic response phenotypes and to identify the genes responsible for these phenotypic differences. The ultimate goal has been to use an understanding of these relations to devise novel personalized pharmacological treatment strategies that maximize the potential for therapeutic benefit and minimize the risk of adverse effects for any given medication. Advances in DNA sequencing and polymorphism characterization technologies have enabled an evolution from the sole reliance on hypothesis-driven approaches to the use of discovery-oriented, genome-wide approaches that require fewer prior assumptions regarding genetic variants. Candidate gene approaches resulted primarily in the identification of genetic variants in drug-metabolizing genes with large effects on toxicity or response [10] ; however, many GWASs have identified novel associations between drug response and genetic variants with unknown functional relevance and often with relatively small effect sizes [11] . The recent development of high-throughput sequencing techniques has enabled researchers to begin to examine the contribution of rare variants to drug sensitivity [12] . Although many important discoveries have been made, several challenges remain before the dream of personalized medicine can be realized. First, researchers must move from collecting large numbers of identified genetic variants to systematically analyzing them. Second, ways must be found to turn this systematic biological understanding into clinical strategies for treatment.
Genome-Wide Association Studies (GWASs)
Since 2007, GWASs have emerged as a powerful tool to identify disease-related genes for many common human disorders and other phenotypes [13] . The National Human Genome Research Institute [14] and the Centers for Disease Control and Prevention both maintain online resources for tracking published GWASs. GWASs are characterized by the need for very large study populations and replication samples because the expected effect sizes are small, and the expected number of false-positive findings is large [15, 16] . It has potential to identify genetic risk factors leading to prevention and treatment of common diseases. The first ever GWA study was probably published in 2002 by Ozaki, in which an association between the LTA gene and myocardial infarction was developed. Another pioneering GWA study by Klein et al. in 2005 reported an association between the CFH gene and age-related macular degeneration. Although there are still many candidate gene studies being performed, the advent of GWAS has added an impetus to identify novel pharmacogenetic associations that might have greater potential clinical use in the future ( Table 1 ). The guidelines produced by journals on GWAS include the need for 'replication sets' of patients [17] , which hopefully will reduce the problem of the 'winners curse.' Multicenter collaborations have also been facilitated to increase sample sizes. A review of the GWAS undertaken in pharmacogenomics was published in 2010 by Daly [18] . The initial GWAS published in complex diseases, particularly those from The Wellcome Trust Case-Control Consortium [19] , were undertaken on at least 2,000 cases. Subsequently, in many studies, such as those on type II diabetes, the sample size has been increased to more than 40,000 [20] . Although at least 38 loci have been identified, few have exceeded relative risks of 1.5, and they are therefore unlikely to be used as genetic predictive tests [21] . For example, for type II diabetes, the genetic loci identified add less than 5 % to the risk prediction that can be determined by clinical factors alone [22] . Fortunately, even with the small number of GWASs undertaken for drug response to date, it seems that the genetic effect size is much 
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[ 94] greater than that seen for complex diseases. GWASs with sample sizes as low as 22 have produced highly significant findings [23] . A typical example of a successful GWAS was for statin-induced myopathy. The SEARCH collaborative undertook a GWAS in 80 subjects with definite or incipient myopathy with 80 mg/day of simvastatin [24] . The association was replicated in patients on 40 mg of simvastatin and has subsequently also been replicated by other investigators [25] . Although this association seems to be important for simvastatin-induced myopathy, whether it is also important for the other statins still requires further study [26] . As with GWAS in complex diseases, a finding that might not show clinical value might still be of use in identifying the mechanism(s) of action of the drug [27 • , 28 • , 29 • ]. For example, the glycemic response to metformin, a first-line therapy for type 2 diabetes mellitus, has recently been shown to be linked to SNPs near the ataxia telangiectasia mutated gene [30] , which is involved in cell cycle control and DNA repair. This provides novel insights into the mechanism of action of metformin, a tantalizing link between diabetes and cancer [31] , and at least a partial explanation of the role of metformin as an anti-tumor agent [32] . It has become commonplace in the genetics community to recognize that genome-wide association studies have led to the identification of hundreds of SNPs as ''risk variants'' for common diseases, while acknowledging that most of the heritability for these traits remains to be explained. We further suggest that many GWAS findings stem from factors other than a true association with disease risk. The bases of our concern are both statistical and experimental.
GWAS Approach: Linkage Disequilibrium
Two approaches have been used to demonstrate the biological importance of risk variants detected in GWAS. One hypothesis is that a risk variant is not itself a critical functional variant, but is in linkage disequilibrium in a subset of cases with a rarer mutation of clear functional effect. The principle is that linkage disequilibrium (or LD) of risk variants with rare mutations of functional effect leads to statistical associations in genome-wide association studies [33] .
GWAS Approach: Distant Regulators
The second approach to demonstrating the biological importance of risk variants detected in GWAS is to assess whether a risk variant regulates a gene at considerable genomic distance from the locale of the SNP. It is well established that mutations in noncoding sequences far removed from coding sequence can alter gene expression and lead to a severe phenotype [34, 35] .
GWASs in Pharmacogenomics: Opportunities
Pharmacogenomics has often been represented as the leading edge in translating human genomic research for clinical practice, creating the basis for personalized medicine [36, 37] . It examines inter-individual variation in drug effects as a function of genetic variation by integrating epidemiological, genetic, pharmacological and clinical measurements. The GWAS approach has succeeded in discovering new associations with adverse drug effects, even though the biological mechanisms may be obscure. An example is the recent identification of a common variant in the SCLO1B1 gene that markedly increases the risk of statin-induced myopathy [38] . The investigators estimated that 60 % of incident myopathy could be attributed to the newly identified variant. GWASs have also found genetic variants associated with individual responses to drugs, including analgesics and chemotherapeutic agents [39, 40] . GWASs have been recognized as an important approach for uncovering polymorphisms accounting for individual differences in drug efficacy and drug safety [41] . A vast reservoir of observational studies and randomized clinical trials (RCTs) provides a largely untapped resource for pharmacogenomic studies of drug safety and efficacy. Performing GWASs within clinical trials, in which more potentially interacting variables can be identified, measured and controlled, improves efficiency. Khoury and Wacholder [42] stressed that effects measured in GWASs will be correct only when gene-environment interactions are taken into account.
GWASs in Pharmacogenomics: Challenges
GWASs in pharmacogenomics also present challenges. So far, most such studies have included far fewer participants (average approximately 200) than the very large sample sizes typical of GWASs of common diseases [43] . Nevertheless, even small pharmacogenomic GWASs have been successful in identifying robust associations because reducing variability in the definition and ascertainment of exposure and outcome increases their power to detect clinically meaningful effects. Nevertheless, larger studies will be required to detect smaller or less common effects. The absolute cost of GWASs in pharmacogenomics remains as high as in other fields, but the marginal cost of genotyping is small, as Roses [44] recently pointed out. A coordinated approach to GWASs in RCTs could lead to more efficient pharmacogenomic research. A first step would be to collect appropriate biological samples from all clinical trial participants with their informed consent for future pharmacogenomic research studies. Many of the drug adverse effects are rare, coming to light only after a drug becomes available for widespread use [45] . Clinical trial participants are a key reference population for subsequent investigation of adverse effects in case-control GWASs. So far, only two GWASs have been conducted in drug clinical trials; each of these studies provides relevant insights for future research. A study of electrocardiographic abnormalities during iloperidone treatment of schizophrenia [46] illustrated the feasibility of performing GWASs in a phase III clinical trial evaluating the efficacy, safety and tolerability of a novel drug. A report on statinrelated myopathy demonstrated the efficiency of performing a nested case-control GWAS within a clinical trial. The National Institutes of Health has recently established funding priorities and requirements for GWASs in government-funded clinical trials [47] . In parallel, the prevailing method of reporting results-typically limited to novel 'GWAS hits' or to one candidate gene at a timeshould be revisited. Comprehensive reporting of GWASs resulting in standardized formats will enhance opportunities for evidence synthesis through meta-analysis [48 • ]. Thus, GWASs can not only identify novel associations for further study, but can also help counter the selective reporting and pursuit of false-positive findings that may occur when pharmacogenomic studies are limited to candidate genes [49] .
End of the Beginning: Common Problems of GWASs
Today, the initial enthusiasm for GWASs is decreasing, and the GWAS society is facing severe criticisms. A frequent complaint is that GWAS results mean little to patients because of the small effect of variants on disease risk and their relatively small contribution to the common disease etiology. In the first place, ''significantly associated'' does not mean that the association identified by the study is significant in biology, medicine or actual life. For example, a paper reported the identification of a SNP that is associated with height, but its estimated additive effect is only 0.44 cm on height [50] . However, the low risk (low odds ratio) is not always due to the GWAS itself. In many studies, it is the problem of particular studies themselves, not of the GWAS. For example, using pooled controls of general populations as controls of highly prevalent diseases, such as diabetes mellitus, hypertension and obesity, must decrease the odds ratio of the susceptibility alleles because of contamination of the patients in the controls. Thus, it is necessary to detect population stratification prior to association analysis. Moreover, a GWAS is not a method to conclude something. It's a method to map the gene: an associated variant is not necessarily a true causal variant. GWASs present candidates of the causal variant. To identify and prove the causality, we need to find the best associated variations by fine mapping around the smoking gun GWAS signal, followed by functional studies for them. Statistics must lead to biology. Biology must lead to medicine. We have already known that there are so many non-protein-coding genes: the genes encoding functional RNAs [51] . They are quite compatible with the original concept of the gene: information in the genome that determines phenotype or trait. To code proteins is just one of the many ways to determine the phenotype.
Still Other Problems of GWASs: Lessons for the Future
GWASs have many false positives. Therefore, association needs replication, but repeating in the same population is not a good idea; it might just introduce the same error as in the first study, which is sometimes difficult to detect. Studies in different populations, preferably in populations from different ethnic groups, are desirable. Multiple replications in large samples provide the most straightforward path for identifying robust and broadly relevant associations, which need international collaboration.
Real Value of GWASs
GWAS is a method to identify a marker for genetic diagnosis and risk assessment. By knowing the genetic risk, we can reevaluate and modify our lifestyles and prevent problems, such as side effects of drugs. Through functional analysis of a gene and its associated variants, we can approach the mechanism of the disease. By studying the meaning of allelic differences of causal variants, we can clarify the molecular pathogenesis of the disease. With knowledge of the pathogenesis, we can walk directly to develop innovative treatments and discover new drugs. Therefore, identification of the significantly associated SNP is just the 'end of the beginning' to get to the final goal: treatment of patients with common diseases.
Next-Generation Sequence Technology
The development of NGS platforms represents a great advance in technology. In comparison to Sanger sequencing, the NGS platforms are able to produce orders of magnitude more sequence data through massively parallel processes, which result in substantial quantities of data at a low cost per base. NGS can be performed on several commercial platforms, including Roche 454 (http://www. 454.com/), Illumina (http://www.illumina.com/) and the SOLiD platform from Life Technologies (http://www. lifetechnologies.com). Broadly speaking, the processes followed by these platforms are similar and include: template preparation (genomic or cDNA) by shearing to create fragment libraries, massive parallel clonal amplification of individual DNA molecules and then sequencing to generate short reads. Finally, an informatic alignment of the short reads is performed to reconstruct the starting template sequence. Third-generation platforms under development include zeromode waveguides; semiconductor and nanopore sequencing technologies promise even larger and faster data generation, although they are a few years away from robustly achieving this [52, 53] , (http://www. iontorrent.com).
Next-Generation Sequencing Platforms
Among the six commercially available platforms, the Roche/454 FLX, Illumina/Solexa Genome Analyzer and Applied Biosystems (ABI) SOLiD Analyzer are currently dominating the market. The other three platforms, the Polonator G.007, Helicos HeliScope and Pacific Biosciences, have already been introduced. Methodologies used by each of the currently available NGS systems are discussed in Table 2 .
Role of the NGS in Early Diagnostic and Treatment
NGS technologies have delivered on their promise of sequencing DNA at unprecedented speed, thereby enabling impressive scientific achievements and novel biological applications [54] . For the first time, NGS has allowed the identification of all mutations/polymorphisms in an organism at the genomic level. For example, using NGS, drug-resistance alleles in Mycobacterium tuberculosis were identified [55] . We already know that quite often a polymorphism is found associated with a disorder. Scientists usually explain this by hidden population stratification between cases and controls, small sample sizes and extensive genetic heterogeneity [56] . Therefore, finding an association between a polymorphism and a disorder in a particular cohort would also depend on the presence of related polymorphisms in other genes in the same cohort. The NGS is providing this opportunity to correlate polymorphisms in functionally related genes. Therefore, by generating a database of linked polymorphisms leading to each disorder, NGS can also be used for identifying high risks of developing disorders even before they have occurred in individuals and take prevention measures where possible.
NGS for the Masses?
The rapidly dropping cost of genome sequencing, now within the $3,000-$5,000 range on a research basis, has even prompted many to believe that it will one day be feasible for the majority of people to have their genomes sequenced. Ashley and colleagues [57 • ] used information gleaned from the whole genome of a patient to develop an entire disease risk profile including a high genetic risk for CAD. This information in collaboration with pharmacogenomic data that indicated the patient would tolerate a statin without adverse effects led to a clinical decision to prescribe a statin in a case where traditional risk factors were borderline. Pan and Knowles [58] expanded on this kind of analysis by using family information using a quartet of genomes from a nuclear family not only to explain the father's hypercoagulable state but also to estimate the heritable risk of this condition in the children using phasing algorithms to identify how alleles were passed within the family. More recently, Chen et al. [59 •• ] used an approach of combined genomic, transcriptomic, proteomic, metabolomic and autoantibody information to detect a high genetic risk for diabetes in an individual who was not suspected based on traditional risk factors.
Application of NGS
NGS is proving a powerful tool in characterizing tumor cells at the genomic, transcriptomic and epigenetic levels [60, 61] . The high sensitivity of NGS in detecting sequences present at low levels means NGS can be used as a quality-control tool to detect adventitious viruses in vaccines, using a metagenomics approach [62, 63] . NGS has already been applied to numerous resequencing studies, which have led to whole-genome sequencing of complete normal and cancer genomes [64, 65, 66 • , 67 • ] and for treatment responses in severe sepsis [68 • ]. NGS is also finding application in the study of short RNAs. A comprehensive study of miRNA in acute myeloid leukemia was performed using NGS, with novel findings of differentially [69] . NGS has been clearly demonstrated to detect low-abundance HIV drug-resistant variants [70] . NGS has also been successfully used to identify novel drug targets [56, 71] .
Current Strategies for the NGS Project
To ensure the correct identification of genetic variants, short-read coverage must be sufficient to ensure the complete and accurate sequence assembly. Currently, coverage of at least 30 is recommended in whole-genome scans for rare genetic variants in human genomes, which is a burden on computer resources and cost management. Although the cost of whole-genome sequencing has dropped substantially, the cost remains a major obstacle; whole-genome sequencing of a single individual currently costs approximately $100,000.00. By targeting specific regions of interest, selective DNA enrichment techniques improve the overall cost and efficiency of NGS [72] ; however, targeted enrichment must maintain uniform coverage, high reproducibility, and no allele bias for any genomic region [73] . Commercially available products for targeted sequence enrichment include Agilent's SureSelect and NimbleGen's SeqCap/EZ Exome (both array-and solution-based technologies), RainDance and Illumina's TruSeq (solutionbased technology), Febit's HybSelect and LC Sciences (microarray-based strategy), Qiagen and Fluidigm (PCRbased method).
Integration of Genomic Testing into Clinical Practice
Despite the optimism expressed regarding the impact of genomic testing, the fact that incorporation of genetics and genomics into patient management guidelines has largely failed to occur thus far can likely be attributed to three realities. First, researchers, diagnostic firms and the regulatory authorities are still seeking to establish methodologies by which to judge their effectiveness. Second, practicing clinicians and guideline writers are still working to understand how such new tests fit into current models of care and risk assessment. Finally, payers are just beginning to foresee new pressures to cover the additional costs. A framework has been proposed to assist in genetic testing evaluation, establishing the technical capabilities and operational standards of the test(s), the diagnostic capabilities and impact on clinical decision making, how the test will be integrated with existing physician behaviors and norms, cost effectiveness and health outcomes [74] .
Conclusion
Recent rapid advances in genetic research are ushering us into the genome sequence era, where an individual's genome information is utilized for clinical practice (Fig. 1) . Pharmacogenomic studies over the past 3 decades have resulted in an overwhelming amount of evidence showing that genetic variation plays a major role in drug response variability. Over the past few years, GWAS has provided some interesting findings that include large and small effects of polymorphisms on drug response and toxicity. Over the next few years, more comprehensive studies involving GWAS and NGS are likely to dominate the field. Finally, the Achilles heel of this field is the implementation of findings into clinical practice. This is being tackled by several large academic centers focused on the implementation of pharmacogenomic discoveries in routine clinical care to help guide clinical decisions. However, the true challenge will be in the adoption of these tests by mainstream physicians.
